|
![]() |
|||
|
||||
OverviewReveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States. This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations. Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants. Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence highlights historical studies of dietary trials designed to reduce CHD covers tests of HMG CoA reductase inhibitors for patients with and without CHD illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol and more! Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines. Full Product DetailsAuthor: Scott M. GrundyPublisher: Taylor & Francis Ltd Imprint: CRC Press Weight: 1.133kg ISBN: 9780367399320ISBN 10: 0367399326 Pages: 352 Publication Date: 19 September 2019 Audience: College/higher education , Postgraduate, Research & Scholarly Format: Paperback Publisher's Status: Active Availability: In Print ![]() This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsCholesterol-Lowering Clinical Trials: A Historical Perspective Scott M. Grundy Scandinavian Simvastatin Survival Study (4S) Terje R. Pedersen The Cholesterol and Recurrent Events Trial (CARE): The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels Frank M. Sacks, Marc A. Pfeffer, Lemuel A. Moyé, C. Morton Hawkins, Barry R. Davis, Jean L. Rouleau, Thomas G. Cole, and Eugene Braunwald Lessons from the West of Scotland Coronary Prevention Study (WOSCOPS) James Shepherd and Allan Gaw Program on the Surgical Control of the Hyperlipidemias (POSCH) Trial: A Pivotal 25-Year Study Henry Buchwald The Air Force/Texas Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Primary Prevention of Acute Major Coronary Events in Women and Men with Average Cholesterol Stephen Weis, Michael Clearfield, Lt. Col. John R. Downs, and Antonio M. Gotto, Jr. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study: Clinical Implications for Cardiovascular Practice Andrew M. Tonkin and David Hunt Angiographic Results of Lipid-Lowering Trials: A Systematic Review and Meta-Analysis Cheryl L. Holmes, Michael Schulzer, and G. B. John Mancini Biochemical Correlates of Plaque Progression and Coronary Events Melissa Ferraro-Borgida and David Waters Lipid Therapy to Stabilize the Vulnerable Atherosclerotic Plaque: New Insights into the Prevention of Cardiovascular Events B. Greg Brown and Xue-Qiao Zhao Cholesterol-Lowering Trials with Carotid Ultrasonographic Outcomes Robert P. Byington Cholesterol Lowering Reduces Mortality: The Statins David J. GordonReviewsAuthor InformationScott M. Grundy Tab Content 6Author Website:Countries AvailableAll regions |